- Home
- Publications
- Publication Search
- Publication Details
Title
PCSK9-Inhibitoren
Authors
Keywords
PCSK9, Sicherheit, Cholesterin, Risiko, Review, Proprotein convertase subtilisin-kexin type 9, Safety, Cholesterol, Risk, Review
Journal
HERZ
Volume 41, Issue 4, Pages 296-306
Publisher
Springer Nature
Online
2016-05-21
DOI
10.1007/s00059-016-4429-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
- (2015) Rainer Schulz et al. BASIC RESEARCH IN CARDIOLOGY
- LDL-Cholesterin: Von der Hypothese zur Kausalität
- (2015) Florian Custodis et al. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
- National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
- (2015) Terry A. Jacobson et al. Journal of Clinical Lipidology
- Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both
- (2015) Brian A. Ference et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Moving beyond the “LDL hypothesis”
- (2015) Christian Werner et al. Vasa-European Journal of Vascular Medicine
- Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)
- (2014) Daniel Gaudet et al. AMERICAN JOURNAL OF CARDIOLOGY
- Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms
- (2014) Shirya Rashid et al. CIRCULATION
- Design and Rationale of the GAUSS-2 Study Trial: A Double-Blind, Ezetimibe-Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy
- (2014) Leslie Cho et al. CLINICAL CARDIOLOGY
- Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial
- (2014) Patrick M. Moriarty et al. Journal of Clinical Lipidology
- Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
- (2014) Susan Kühnast et al. JOURNAL OF LIPID RESEARCH
- Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
- (2014) Frederick J. Raal et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
- (2014) Gergana Galabova et al. PLoS One
- PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
- (2013) Emile Levy et al. ATHEROSCLEROSIS
- Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
- (2013) Evan A. Stein et al. CIRCULATION
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
- (2013) B. G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
- (2013) Daniel Urban et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
- (2012) Maxime Denis et al. CIRCULATION
- Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease
- (2012) Brian A. Ference et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
- (2011) et al. EUROPEAN HEART JOURNAL
- Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
- (2009) Cédric Le May et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now